Eli Lil­ly li­cens­es pre­clin­i­cal an­ti­sense pro­gram de­signed to treat ALS, de­men­tia

Eli Lil­ly added an­oth­er neu­ro­science pro­gram to its pipeline, li­cens­ing an an­ti­sense oligonu­cleotide from the ALS biotech QurAlis.

The deal, an­nounced Mon­day, is the lat­est …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER